# OnCo record china-vbp-nrdl (term). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/terms/china-vbp-nrdl/>
  a schema:DefinedTerm ;
  onco:kind "term" ;
  schema:identifier "china-vbp-nrdl" ;
  schema:name "China National Reimbursement Drug List negotiation and volume-based procurement"@en ;
  schema:alternateName "NRDL"@en, "National Reimbursement Drug List"@en, "NRDL negotiation"@en, "volume-based procurement"@en, "VBP"@en, "4+7 pilot"@en, "national volume-based procurement"@en, "NHSA negotiation"@en ;
  schema:description "China's two price levers: an annual negotiation, since 2017, in which a new cancer drug wins national reimbursement only by cutting its price, often by half or more, and tenders since 2018 in which generic makers bid for guaranteed hospital volumes, collapsing prices of off-patent drugs."@en ;
  schema:url <https://onco.cc/terms/china-vbp-nrdl/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/National_Healthcare_Security_Administration> ;
  schema:citation <https://en.wikipedia.org/wiki/National_Healthcare_Security_Administration> ;
  onco:tag "law", "cn" ;
  onco:related <https://onco.cc/terms/hta/>, <https://onco.cc/terms/drug-price-transparency/>, <https://onco.cc/terms/china-drug-administration-law/>, <https://onco.cc/terms/inflation-reduction-act/>, <https://onco.cc/terms/amnog/>, <https://onco.cc/terms/biosimilar/>, <https://onco.cc/technologies/global-oncology-access/>, <https://onco.cc/terms/who-essential-medicines/>, <https://onco.cc/terms/financial-toxicity/> ;
  onco:drugs <https://onco.cc/drugs/imatinib/> ;
  onco:institutions <https://onco.cc/institutions/nhsa/>, <https://onco.cc/institutions/nmpa-cde/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-drug-pricing/>, <https://onco.cc/bottlenecks/b-global-access/> .